Protalix BioTherapeutics, Inc.
Income Statement
| Line Item | FY2010 | FY2009 |
|---|---|---|
| Revenue | $6.6M | $388.0K |
| Cost of Revenue | $4.4M | $3.6M |
| Gross Profit | $6.9M | $-3.2M |
| Gross Margin | 103.3% | -821.4% |
| Operating Expenses | ||
| Research & Development | $37.7M | $27.4M |
| SG&A Expense | $6.9M | $7.1M |
| Operating Income | $-30.0M | $-32.0M |
| Operating Margin | -451.2% | -8,239.4% |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | $-29.0M | $-31.4M |
| Net Margin | -436.6% | -8,103.1% |
| EPS (Basic) | $-0.36 | $0.41 |
| EPS (Diluted) | $-0.36 | $0.41 |
| Shares Outstanding (Basic) | 81.2M | — |
| Shares Outstanding (Diluted) | 81.2M | — |
| Dividends Per Share | — | — |